MedDataX Logo

Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children

NCT ID: NCT00521703

Last Updated: 2008-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is some controversy in the medical literature regarding the effectiveness of topical lidocaine in children as an adjuvant drug to upper gastrointestinal endoscopy. In children, deep sedation and general anesthesia are often used to sedate children submitting to this procedure. Propofol is an anesthetic drug increasingly popular in this situation, but this drug can only be used with an anesthesiologist in Brazil. Its main side effects include hypotension, respiratory depression and local pain. Lidocaine is frequently used as premedication, and the rationale is that lowering patient discomfort could lower the required dose to achieve the endoscopy and reduce potential side effects. Nevertheless, some patients perceive this medication as uncomfortable. This study aims to compare sedative drug doses between patients who were given either placebo or topical lidocaine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized double-blind placebo-controlled clinical trial.

Primary outcome: propofol doses required to achieve adequate sedation.

Population: children submitting to upper digestive endoscopy, weight \> 30 kg and age between 8 and 18 years.

Exclusion criteria: neurological disorders, psychiatric disorders, specific contra-indication to either lidocaine or propofol.

Estimated sample: 160 patients. Placebo: tannic acid 0.5%

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspepsia Malabsorption Syndrome Gastroesophageal Reflux Disease Abdominal Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

endoscopy, gastrointestinal lidocaine propofol child adolescent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

group treated

Group Type EXPERIMENTAL

Lidocaine

Intervention Type DRUG

oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing

2

control group

Group Type PLACEBO_COMPARATOR

Tannic acid

Intervention Type DRUG

oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing

Intervention Type DRUG

Tannic acid

oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children and adolescents submitting to upper digestive endoscopy with weight above 30 kg and age between 8 and 18 years

Exclusion Criteria

* Neurological disorders
* Psychiatric disorders
* Specific contra-indication to lidocaine
* Specific contra-indication to propofol
Minimum Eligible Age

8 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Infantil Cândido Fontoura

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rodrigo S Machado, PhD

Role: PRINCIPAL_INVESTIGATOR

UNIFESP/EPM

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Infantil Cândido Fontoura

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HICF 001-07

Identifier Type: -

Identifier Source: org_study_id